Skip to main content

Embecta Corp. (EMBC) Stock Forecast 2025 - AI Price Prediction & Analysis


Embecta Corp. (EMBC) AI Stock Price Forecast & Investment Analysis

Embecta Corp. Stock Price Chart and Technical Analysis

Loading Embecta Corp. interactive price chart and technical analysis...

Embecta Corp. (EMBC) - Comprehensive Stock Analysis & Investment Research

Deep dive into Embecta Corp.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Embecta Corp., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Embecta Corp.: Embecta Corp. operates in the Industrial Applications and Services sector, making it an emerging small-cap investment.

Embecta Corp. (Stock Symbol: EMBC) is a leading company in the Industrial Applications and Services sector , specifically operating within the Surgical & Medical Instruments & Apparatus industry.

The organization employs approximately 77 professionals worldwide .

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Embecta Corp.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Embecta Corp.: With $289M in annual revenue and 27.1% net margin, the company demonstrates exceptional profitability.

Annual Revenue: $289 million generating a 27.1% net profit margin .

Market Capitalization: $822 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): 74.2% - Exceptional shareholder return efficiency, indicating strong management effectiveness.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Embecta Corp. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Embecta Corp.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Embecta Corp. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Embecta Corp.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Embecta Corp.: Strong free cash flow generation demonstrates solid operational efficiency.

Embecta Corp. strategically competes in the highly dynamic Surgical & Medical Instruments & Apparatus marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company demonstrates robust operational efficiency through strong free cash flow generation of $505 million annually.

The company maintains a healthy 254.1% gross margin, indicating strong pricing power and operational efficiency.

Embecta Corp. (EMBC) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Embecta Corp. stock analysis.

Loading Embecta Corp. comprehensive fundamental analysis and insider trading data...

Deep dive into Embecta Corp.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Embecta Corp. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Embecta Corp.: With a P/E ratio of 15.82, the market moderately values the company's earnings.

P/E Ratio 15.82x
P/B Ratio -0.78x
Market Cap $822M
EPS $1.34
Book Value/Share $-12.62
Revenue/Share $19.40
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Embecta Corp. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Embecta Corp.: An ROE of 74.2% demonstrates excellent shareholder value creation.

ROE 74.2%
ROA 45.6%
ROIC 74.2%
Gross Margin 254.1%
Operating Margin 57.7%
Net Margin 27.1%
EBT Margin 39.0%
Tax Rate 15.9%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Embecta Corp.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Embecta Corp.: A current ratio of 2.53 indicates strong liquidity.

Current Ratio 2.53x
Quick Ratio 1.65x
Financial Leverage 1.34x
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Embecta Corp.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Embecta Corp.: Free cash flow of $505M provides flexibility for shareholder returns and growth investments.

Operating Cash Flow $536M
Free Cash Flow $505M
Capital Spending $-30M
FCF/Sales 43.6%
CapEx/Sales 2.7%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Embecta Corp. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Embecta Corp.: An asset turnover of 1.39x demonstrates efficient asset utilization.

Asset Turnover 1.39x
Receivables Turnover 76.3x
Inventory Turnover 2.9x
Fixed Assets Turnover 3.3x
Days Sales Outstanding 5 days
Days Inventory 127 days
Payables Period 53 days
Cash Conversion Cycle 79 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Embecta Corp.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Embecta Corp.: With annual revenue of $289M, Embecta Corp. demonstrates solid business size.

Income Statement ($ Millions)
Total Revenue $289M
Operating Income $116M
R&D Expense $79M
SG&A Expense $22M
Cost of Goods Sold $388M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 51%
Cash & Short-term Investments 32%
Total Liabilities 216%
Short-term Debt 1%
Accounts Receivable 2%
Inventory 15%
Dividend & Shareholder Information
Shares Outstanding 58M
Growth Metrics (YoY)
EPS Growth 6.7%

Latest Embecta Corp. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Embecta Corp. (EMBC) stock price and investment outlook.

, source: Seeking Alpha

Welcome, ladies and gentlemen, to the Fiscal Third Quarter 2023 Embecta Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded and that the recording ...

, source: MarketWatch

Visit a quote page and your recently viewed tickers will be displayed here. David J. Albritton is the founder of Nineteen88 Strategies LLC. He currently holds the position of Director at Points of ...

Embecta Corp. Competitors & Peer Analysis - Industrial Applications and Services Sector

Comparative analysis of Embecta Corp. against industry peers and competitors in the Industrial Applications and Services sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ADGM Unlock Forecast - 30 Days FREE Trial $21M x 2.4x
ALUR Unlock Forecast - 30 Days FREE Trial $15M -0.4x -0.3x
ANGO Unlock Forecast - 30 Days FREE Trial $510M -1.4x 2.9x
ANIK Unlock Forecast - 30 Days FREE Trial $144M -4.3x 1.0x
AORT Unlock Forecast - 30 Days FREE Trial $1991M -198.2x 4.7x
APYX Unlock Forecast - 30 Days FREE Trial $116M -3.5x 16.1x
ARAY Unlock Forecast - 30 Days FREE Trial $177M -9.9x 2.2x
ATEC Unlock Forecast - 30 Days FREE Trial $2468M -7.4x 103.8x
ATRC Unlock Forecast - 30 Days FREE Trial $1812M -39.6x 3.9x
AVHHL Unlock Forecast - 30 Days FREE Trial $30M x x
BAX Unlock Forecast - 30 Days FREE Trial $11750M -94.9x 1.6x
BBNX Unlock Forecast - 30 Days FREE Trial $1069M x 3.5x
BDX Unlock Forecast - 30 Days FREE Trial $53180M 34.1x 2.1x
BEAT Unlock Forecast - 30 Days FREE Trial $58M -5.7x 13.9x
BJDX Unlock Forecast - 30 Days FREE Trial $4M -0.5x 0.7x
BSX Unlock Forecast - 30 Days FREE Trial $150779M 61.0x 6.7x
BVS Unlock Forecast - 30 Days FREE Trial $477M -18.3x 3.0x
CARL Unlock Forecast - 30 Days FREE Trial $60M x x
CERS Unlock Forecast - 30 Days FREE Trial $284M -13.8x 5.1x
CLPT Unlock Forecast - 30 Days FREE Trial $718M -23.5x 36.4x
CODX Unlock Forecast - 30 Days FREE Trial $12M -0.7x 0.3x
CVRX Unlock Forecast - 30 Days FREE Trial $280M -5.5x 4.8x
DCTH Unlock Forecast - 30 Days FREE Trial $355M 160.2x 3.4x
DRTS Unlock Forecast - 30 Days FREE Trial $362M x 4.2x
DXCM Unlock Forecast - 30 Days FREE Trial $27152M 49.1x 10.6x
EBRCZ Unlock Forecast - 30 Days FREE Trial $427M x 8.6x
EMBC Unlock Forecast - 30 Days FREE Trial $822M 15.8x -0.8x
FEMY Unlock Forecast - 30 Days FREE Trial $23M -1.4x 15.2x
FOFA Unlock Forecast - 30 Days FREE Trial $7M x 12.7x
GIPL Unlock Forecast - 30 Days FREE Trial $7M x 36.1x
GKOS Unlock Forecast - 30 Days FREE Trial $4453M -46.3x 5.8x
GMED Unlock Forecast - 30 Days FREE Trial $8668M 24.1x 2.0x
GUTS Unlock Forecast - 30 Days FREE Trial $69M x 13.8x
HAE Unlock Forecast - 30 Days FREE Trial $2466M 26.1x 2.8x
HRGN Unlock Forecast - 30 Days FREE Trial $29M x 38.2x
IART Unlock Forecast - 30 Days FREE Trial $1198M 200.2x 1.2x
ICCM Unlock Forecast - 30 Days FREE Trial $48M x 16.6x
ICUI Unlock Forecast - 30 Days FREE Trial $3034M -49.8x 1.4x
IDXG Unlock Forecast - 30 Days FREE Trial $4M 0.8x -0.9x
IINN Unlock Forecast - 30 Days FREE Trial $27M x 6.2x
IINNW Unlock Forecast - 30 Days FREE Trial $10M x 2.4x
INBS Unlock Forecast - 30 Days FREE Trial $8M -0.3x 2.7x
INFU Unlock Forecast - 30 Days FREE Trial $207M 40.8x 3.8x
INSP Unlock Forecast - 30 Days FREE Trial $2312M 43.2x 3.4x
IRMD Unlock Forecast - 30 Days FREE Trial $987M 48.3x 10.5x
IRTC Unlock Forecast - 30 Days FREE Trial $5865M -20.2x 56.6x
KIDS Unlock Forecast - 30 Days FREE Trial $390M -20.7x 1.1x
KMTS Unlock Forecast - 30 Days FREE Trial $1438M x x
KRMD Unlock Forecast - 30 Days FREE Trial $196M -19.8x 11.9x
LMAT Unlock Forecast - 30 Days FREE Trial $2063M 43.4x 5.7x
LNSR Unlock Forecast - 30 Days FREE Trial $143M -6.7x -7.0x
LUCD Unlock Forecast - 30 Days FREE Trial $130M -0.6x 16.6x
LUNG Unlock Forecast - 30 Days FREE Trial $62M -4.3x 0.9x
MCAG Unlock Forecast - 30 Days FREE Trial $33M x -9.6x
MCAGU Unlock Forecast - 30 Days FREE Trial $31M x -9.9x
MDNC Unlock Forecast - 30 Days FREE Trial $59M 26.2x 12.2x
MDXG Unlock Forecast - 30 Days FREE Trial $997M 30.5x 4.6x
MGRM Unlock Forecast - 30 Days FREE Trial $217M -10.7x 25.1x
MHUA Unlock Forecast - 30 Days FREE Trial $11M x 0.1x
MMM Unlock Forecast - 30 Days FREE Trial $88624M 26.8x 19.2x
MMSI Unlock Forecast - 30 Days FREE Trial $4903M 41.1x 3.3x
NEPH Unlock Forecast - 30 Days FREE Trial $52M 39.1x 6.2x
NMTC Unlock Forecast - 30 Days FREE Trial $41M -1.7x 5.0x
NPCE Unlock Forecast - 30 Days FREE Trial $351M -10.4x 18.1x
NSPR Unlock Forecast - 30 Days FREE Trial $74M -4.3x 3.6x
NVCR Unlock Forecast - 30 Days FREE Trial $1519M -20.8x 4.4x
NXGL Unlock Forecast - 30 Days FREE Trial $20M -6.8x 4.3x
OBIO Unlock Forecast - 30 Days FREE Trial $153M -3.4x 1.5x
OFIX Unlock Forecast - 30 Days FREE Trial $636M -5.8x 1.4x
OSRH Unlock Forecast - 30 Days FREE Trial $11M x 0.1x
OSUR Unlock Forecast - 30 Days FREE Trial $223M 17.1x 0.6x
PAVM Unlock Forecast - 30 Days FREE Trial $10M 0.1x 0.3x
PDEX Unlock Forecast - 30 Days FREE Trial $93M 10.3x 2.5x
PEN Unlock Forecast - 30 Days FREE Trial $9235M 67.4x 7.1x
PLRZ Unlock Forecast - 30 Days FREE Trial $6M x 0.3x
PLSE Unlock Forecast - 30 Days FREE Trial $1183M -2.6x 11.3x
PMI Unlock Forecast - 30 Days FREE Trial $37M x x
PODD Unlock Forecast - 30 Days FREE Trial $22912M 97.8x 15.7x
PRCT Unlock Forecast - 30 Days FREE Trial $2020M -45.4x 5.2x
PROF Unlock Forecast - 30 Days FREE Trial $165M x 4.2x
PSTV Unlock Forecast - 30 Days FREE Trial $57M -0.3x 18.8x
PYPD Unlock Forecast - 30 Days FREE Trial $51M x 2.5x
RCEL Unlock Forecast - 30 Days FREE Trial $106M -5.0x -29.9x
RDGL Unlock Forecast - 30 Days FREE Trial $35M x 13.0x
RMD Unlock Forecast - 30 Days FREE Trial $37558M 27.7x 6.3x
RSMDF Unlock Forecast - 30 Days FREE Trial $3625M 2.6x 0.6x
RTGN Unlock Forecast - 30 Days FREE Trial $66M x x
RVP Unlock Forecast - 30 Days FREE Trial $27M -0.9x 0.4x
SGHT Unlock Forecast - 30 Days FREE Trial $275M -3.7x 3.9x
SIBN Unlock Forecast - 30 Days FREE Trial $676M -14.3x 4.0x
SKIN Unlock Forecast - 30 Days FREE Trial $185M -1.8x 2.5x
SNOA Unlock Forecast - 30 Days FREE Trial $6M -5.6x 1.6x
SNWV Unlock Forecast - 30 Days FREE Trial $266M x -19.4x
SOLV Unlock Forecast - 30 Days FREE Trial $12297M 32.9x 3.4x
SRTS Unlock Forecast - 30 Days FREE Trial $53M 31.6x 1.0x
SSKN Unlock Forecast - 30 Days FREE Trial $8M -8.0x 25.6x
STIM Unlock Forecast - 30 Days FREE Trial $206M -1.0x 7.6x
STME Unlock Forecast - 30 Days FREE Trial $20M x x
STSS Unlock Forecast - 30 Days FREE Trial $5M -2.5x 0.3x
SYK Unlock Forecast - 30 Days FREE Trial $145259M 50.7x 12.4x
TCMD Unlock Forecast - 30 Days FREE Trial $342M 22.3x 1.8x
TELA Unlock Forecast - 30 Days FREE Trial $61M -1.8x 6.6x
TFX Unlock Forecast - 30 Days FREE Trial $5892M 31.0x 1.4x
TLSI Unlock Forecast - 30 Days FREE Trial $187M -3.6x -5.6x
TMCI Unlock Forecast - 30 Days FREE Trial $430M -7.5x 4.4x
TNDM Unlock Forecast - 30 Days FREE Trial $1031M -17.1x 7.7x
TNON Unlock Forecast - 30 Days FREE Trial $9M -0.3x 1.4x
UFPT Unlock Forecast - 30 Days FREE Trial $1557M 44.7x 4.0x
USAQ Unlock Forecast - 30 Days FREE Trial $2M x x
UTMD Unlock Forecast - 30 Days FREE Trial $194M 15.5x 1.7x
VERO Unlock Forecast - 30 Days FREE Trial $4M 0.0x 1.8x
WST Unlock Forecast - 30 Days FREE Trial $20383M 44.4x 6.7x
XTNT Unlock Forecast - 30 Days FREE Trial $99M -478.8x 2.0x

Frequently Asked Questions - Embecta Corp. Stock Forecast

How accurate are Embecta Corp. stock predictions?

Our AI model shows a 28% Spearman correlation coefficient for EMBC predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Embecta Corp. stock price forecasts?

Our analysis considers Embecta Corp.'s financial metrics, Industrial Applications and Services sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Embecta Corp. a good investment in 2025?

Based on our AI analysis, Embecta Corp. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Embecta Corp. forecasts updated?

Embecta Corp. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Embecta Corp. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Embecta Corp. stock.

My Portfolio

Investment Dashboard

Loading your portfolio...